RT Journal Article SR Electronic T1 Respiratory syncytial viral infections in lung transplant recipients: Treatment with aerolised ribavirin JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P2689 VO 42 IS Suppl 57 A1 Simona Soresi A1 Haifa Lyster A1 Anne Hall A1 Anna Reed A1 Andre Simon A1 Martin Carby YR 2013 UL http://erj.ersjournals.com/content/42/Suppl_57/P2689.abstract AB Respiratory syncytial virus (RSV) is an important cause of serious respiratory illness in lung transplant recipients (LTRs). RSV is a well recognised risk factor for the development of bronchiolitis obliterans syndrome (BOS). Ribavirin has been administered intravenously and orally in the treatment of RSV in adult lung transplantation but reports of its use aerolised is limited. We performed a retrospective analysis of LTRs who received aerolised ribavirin to treat RSV during the period December 2010-12, outcomes included respiratory function tests (RFTs) and adverse drug reactions (ADRs).8 LTRs (2 male) were treated with aerolised Ribavirin for RSV infection, all presented with a drop in RFTs and viral symptoms. 3 patients with histological and/or radiological evidence of interstitial pneumonitis also received intravenous immunoglobulin (500mg/kg daily for 5 days) and high dose corticosteroids. Aerolised Ribavirin was administered as 6g/day at a concentration of 60mg/ml running at 17.5ml/hour for 2 hours every 8 hours until 2 consecutive negative nasopharyngeal aspirate samples were achieved. RFTs were repeated at the end of the treatment course.8 patients (9 treatment episodes) were treated for a mean of 10.6 days (range: 6-22 days). In 6 of the 9 treatment episodes the respiratory symptoms resolved completely, with RFTs returning to baseline. 2 patients died post-treatment (81 and 184 days) and 1 patient developed BOS. There were minor ADRs in 4 patients: sore throat (1), headache (3) and nausea (1), none necessitated treatment discontinuation.In adult LTRs with RSV infections, aerolised ribavirin is a safe and promising treatment option with minimal systemic ADRs.